ClinicalTrials.gg
CompletedNCT04211363DERMIS-1Updated Dec 7, 2022Results posted

Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis

A Phase 3 interventional study of Roflumilast 0.3% cream and Vehicle Cream in Chronic Plaque Psoriasis, sponsored by Arcutis Biotherapeutics, Inc.. Completed at 40 sites in 2 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2022-12-07.

Sponsored by Arcutis Biotherapeutics, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
439
Allocation
Randomized
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing roflumilast in Psoriasis — 3 open to participants now, 3 under way, none of them phase 3. Roflumilast · Psoriasis.

Enrollment
2nd of 17
439 · median 46
Started
2019
with 1 other
Phase 3
5 of 17
none open now
Registered
5th of 17
by date
Lead sponsor
9 of 17
Arcutis Biotherapeutics, Inc.

Among the 17 studies testing roflumilast in Psoriasis, this one is the 2nd largest by enrollment, is one of 2 that started in 2019, is one of 5 in phase 3, and was the 5th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

3 of the 17 studies testing roflumilast in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About roflumilast

Roflumilast: first FDA approval 2011 (DALIRESP), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing roflumilast in Psoriasis, or all of them as a file.
02

Study summary

This is a double-blind, parallel group, vehicle-controlled study to assess the safety and efficacy of roflumilast (ARQ-151) 0.3% cream vs vehicle (placebo) cream for treatment of chronic plaque psoriasis (CPP) in adult participants with 2 to 20% body surface area (BSA) of CPP.

03

Conditions studied

  • Chronic Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants legally competent to sign and give and if appropriate assent as required by local laws
  • Males and females ages 2 years and older (inclusive)
  • Clinical diagnosis of psoriasis vulgaris of at least 6 months duration (3 months for children) as determined by the Investigator
  • Females of (FOCBP) must have a negative pregnancy test at Screening (Visit 1) and Baseline (Visit 2). In addition, sexually active FOCBP must agree to use at least one form of highly effective throughout the trial.
  • In good health as judged by the Investigator, based on medical history, physical examination, serum chemistry labs, hematology values, and urinalysis.
  • Subjects considered reliable and capable of adhering to the Protocol and visit schedule, according to the judgment of the Investigator.

Exclusion criteria

Exclusion Criteria:

  • Planned excessive exposure of treated area(s) to either natural or artificial sunlight, tanning bed or other LED.
  • Females who are pregnant, wishing to become pregnant during the study, or are breast-feeding.
  • Previous treatment with ARQ-151 or its active ingredient
  • Subjects with any serious medical condition or laboratory abnormality that would prevent study participation or place the subject at significant risk, as determined by the Investigator.
  • Subjects with a history of chronic alcohol or drug abuse within 6 months of initiation of product
  • Subjects who are unable to communicate, read or understand the local language, or who display another condition, which in the Investigator's opinion, makes them unsuitable for clinical study participation
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
439 participants (actual)

Study arms

  • Experimental
    Rofumilast Cream 0.3%

    Participants receive roflumilast cream 0.3% once daily for 8 weeks.

    Drug: Roflumilast 0.3% cream

  • Placebo comparator
    Vehicle cream

    Participants receive vehicle cream once daily for 8 weeks.

    Drug: Vehicle Cream

Interventions

  • Roflumilast 0.3% cream for topical application.

    Also known as: ARQ-151

  • DrugVehicle Cream

    Vehicle cream for topical application.

06

What researchers measure

Primary outcomes

  1. Number of Participants Achieving Success in Investigator Global Assessment (IGA) Scale Assessment of Disease Severity at Week 8

    The number of participants achieving "success" in IGA assessment of disease severity at Week 8 is presented (observed data only) for each arm. Success was defined as achievement of an IGA score of 0 ('clear') or 1 ('almost clear') at Week 8, accompanied by a ≥2-grade improvement from baseline IGA score. The IGA is a 5-point scale assessing the severity of plaque psoriasis, with scores ranging from 0 ('clear') to 4 ('severe'), and higher scores indicate greater symptom severity.

    Time frame: Baseline (Day 1) and Week 8

Secondary outcomes

  1. Time to Achieve Psoriasis Area Severity Index-50 (PASI-50)

    The Psoriasis Area and Severity Index (PASI) is widely used for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range from 0 (no disease) to 72 (maximal disease), with higher scores indicating greater symptom severity. The time to achieve PASI-50 (defined as a 50% reduction from baseline in PASI score) is presented, and is based on observed data only.

    Time frame: From start of treatment to achievement of PASI-50 or study completion/early termination (maximum duration = 121 days)

  2. Number of Participants Achieving Psoriasis Area Severity Index 75 (PASI-75)

    The Psoriasis Area and Severity Index (PASI) is widely used for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range from 0 (no disease) to 72 (maximal disease), with higher scores indicating greater symptom severity. The number of participants achieving PASI-75 (defined as a 75% reduction from baseline in PASI score) at Week 8 is presented. Participant counts are based on observed data only.

    Time frame: Baseline (Day 1) and Week 8

  3. Number of Participants Achieving Psoriasis Area Severity Index-90 (PASI-90)

    Psoriasis Area and Severity Index (PASI) is widely used for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range 0 (no disease) to 72 (maximal disease) \[higher scores indicate greater symptom severity\]. The number of participants achieving PASI-90 (defined as a 90% reduction from baseline in PASI score) at Week 8 is presented. Participant counts are based on observed data only.

    Time frame: Baseline (Day 1) and Week 8

  4. Number of Participants Achieving Intertriginous IGA (I-IGA) Success at Week 8

    The number of participants achieving I-IGA success at Week 8 is presented. Success is defined as achievement of I-IGA score of 0 ('clear') or 1 ('almost clear') at Week 8 PLUS a ≥2-grade improvement in score from Baseline. The I-IGA is a 5-point scale assessing the severity of plaque psoriasis in the intertriginous area, with scores ranging from 0 ('clear') to 4 ('severe'), with higher scores indicating greater symptom severity. Participant counts are based on observed data only.

    Time frame: Baseline (Day 1) and Week 8

  5. Number of Participants Achieving Score of 'Clear' in I-IGA at Week 8

    The number of participants achieving an IGA score of 0 ('clear') at Week 8 is presented (observed data only) for each arm. The I-IGA is a 5-point scale assessing the severity of plaque psoriasis, with scores ranging from 0 ('clear') to 4 ('severe'); higher scores indicate greater symptom severity.

    Time frame: Week 8

  6. Number of Participants Achieving Worst Itch Numerical Rating Score (WI-NRS) Success

    The number of participants achieving success in WI-NRS is presented. Success is defined as achievement of a ≥ 4-point reduction in WI-NRS pruritus score in participants with WI-NRS pruritus score ≥ 4 at baseline. The WI-NRS is a 10 point scale ranging from 0 ('no itch') to 10 ('worst itch imaginable'), with higher scores indicating greater symptoms severity. Results are based on observed data only.

    Time frame: Baseline (Day 1) and Weeks 2, 4, and 8

  7. Change From Baseline in Psoriasis Symptoms Diary (PSD) Score

    The PSD is a 16-item questionnaire asking subjects to rate the severity of psoriasis-related symptoms in the past 24 hours. Each question is scored from 0 ("no symptoms") to 10 ("worst imaginable symptoms"). Scores range from 0 to 160, with higher scores indicating greater symptom severity. The least squares (LS) mean (95% CI) change in PSD total score relative to baseline is presented for each treatment arm, with decreases from baseline indicating symptom improvement.

    Time frame: Weeks 4 and 8

07

Results

Posted Nov 3, 2022

Participant flow

Adult male and female participants with chronic plaque psoriasis involving between 2% and 20% body surface area (BSA) \[excluding the scalp, palms, and soles\] were recruited at 43 study sites in the United States and Canada.

Participant flow — Overall Study
MilestoneRofumilast Cream 0.3%Vehicle Cream
Started286153
Completed255133
Not completed3120
Withdrew: Adverse event52
Withdrew: Physician decision01
Withdrew: Protocol violation10
Withdrew: Pregnancy10
Withdrew: Lost to follow-up124
Withdrew: Withdrawal by subject1111
Withdrew: Other12

Outcome measures

PrimaryNumber of Participants Achieving Success in Investigator Global Assessment (IGA) Scale Assessment of Disease Severity at Week 8

The number of participants achieving "success" in IGA assessment of disease severity at Week 8 is presented (observed data only) for each arm. Success was defined as achievement of an IGA score of 0 ('clear') or 1 ('almost clear') at Week 8, accompanied by a ≥2-grade improvement from baseline IGA score. The IGA is a 5-point scale assessing the severity of plaque psoriasis, with scores ranging from 0 ('clear') to 4 ('severe'), and higher scores indicate greater symptom severity.

Time frame:
Baseline (Day 1) and Week 8
Reported as:
Count of participants · Participants
Number of Participants Achieving Success in Investigator Global Assessment (IGA) Scale Assessment of Disease Severity at Week 8
ParticipantsRofumilast Cream 0.3%Vehicle Cream
Number of Participants Achieving Success in Investigator Global Assessment (IGA) Scale Assessment of Disease Severity at Week 81088
Statistical analysis
  • Rofumilast Cream 0.3% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 20.69 · 95% CI 7.58 to 56.48Common odds ratio stratified by pooled study site, baseline IGA, and baseline intertriginous involvement per randomization with multiple imputation of missing data..
SecondaryTime to Achieve Psoriasis Area Severity Index-50 (PASI-50)

The Psoriasis Area and Severity Index (PASI) is widely used for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range from 0 (no disease) to 72 (maximal disease), with higher scores indicating greater symptom severity. The time to achieve PASI-50 (defined as a 50% reduction from baseline in PASI score) is presented, and is based on observed data only.

Time frame:
From start of treatment to achievement of PASI-50 or study completion/early termination (maximum duration = 121 days)
Reported as:
Median · days
Time to Achieve Psoriasis Area Severity Index-50 (PASI-50)
daysRofumilast Cream 0.3%Vehicle Cream
Time to Achieve Psoriasis Area Severity Index-50 (PASI-50)31.0 (29.0 to 41.0)104.0 (85.0 to NA)
Statistical analysis
  • Rofumilast Cream 0.3% vs Vehicle Cream · Log Rank · p = <0.0001 · Hazard ratio (hr): 3.867 · 95% CI 2.795 to 5.351Stratified by pooled study site, baseline IGA, and baseline intertriginous involvement per randomization.
SecondaryNumber of Participants Achieving Psoriasis Area Severity Index 75 (PASI-75)

The Psoriasis Area and Severity Index (PASI) is widely used for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range from 0 (no disease) to 72 (maximal disease), with higher scores indicating greater symptom severity. The number of participants achieving PASI-75 (defined as a 75% reduction from baseline in PASI score) at Week 8 is presented. Participant counts are based on observed data only.

Time frame:
Baseline (Day 1) and Week 8
Reported as:
Count of participants · Participants
Number of Participants Achieving Psoriasis Area Severity Index 75 (PASI-75)
ParticipantsRofumilast Cream 0.3%Vehicle Cream
Number of Participants Achieving Psoriasis Area Severity Index 75 (PASI-75)10610
Statistical analysis
  • Rofumilast Cream 0.3% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 12.00 · 95% CI 5.15 to 27.93Common odds ratio stratified by pooled study site, baseline IGA, and baseline intertriginous involvement per randomization with multiple imputation of missing data.
SecondaryNumber of Participants Achieving Psoriasis Area Severity Index-90 (PASI-90)

Psoriasis Area and Severity Index (PASI) is widely used for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range 0 (no disease) to 72 (maximal disease) \[higher scores indicate greater symptom severity\]. The number of participants achieving PASI-90 (defined as a 90% reduction from baseline in PASI score) at Week 8 is presented. Participant counts are based on observed data only.

Time frame:
Baseline (Day 1) and Week 8
Reported as:
Count of participants · Participants
Number of Participants Achieving Psoriasis Area Severity Index-90 (PASI-90)
ParticipantsRofumilast Cream 0.3%Vehicle Cream
Number of Participants Achieving Psoriasis Area Severity Index-90 (PASI-90)573
Statistical analysis
  • Rofumilast Cream 0.3% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 17.90 · 95% CI 4.38 to 73.09Cochran-Mantel-Haenszel stratified by study site, baseline IGA score, and baseline intertriginous involvement with multiple imputation of missing data.
SecondaryNumber of Participants Achieving Intertriginous IGA (I-IGA) Success at Week 8

The number of participants achieving I-IGA success at Week 8 is presented. Success is defined as achievement of I-IGA score of 0 ('clear') or 1 ('almost clear') at Week 8 PLUS a ≥2-grade improvement in score from Baseline. The I-IGA is a 5-point scale assessing the severity of plaque psoriasis in the intertriginous area, with scores ranging from 0 ('clear') to 4 ('severe'), with higher scores indicating greater symptom severity. Participant counts are based on observed data only.

Time frame:
Baseline (Day 1) and Week 8
Reported as:
Count of participants · Participants
Number of Participants Achieving Intertriginous IGA (I-IGA) Success at Week 8
ParticipantsRofumilast Cream 0.3%Vehicle Cream
Number of Participants Achieving Intertriginous IGA (I-IGA) Success at Week 8374
Statistical analysis
  • Rofumilast Cream 0.3% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 17.94 · 95% CI 2.33 to 138.20Common odds ratio stratified by pooled study site and baseline IGA per randomization with multiple imputation of missing data.
SecondaryNumber of Participants Achieving Score of 'Clear' in I-IGA at Week 8

The number of participants achieving an IGA score of 0 ('clear') at Week 8 is presented (observed data only) for each arm. The I-IGA is a 5-point scale assessing the severity of plaque psoriasis, with scores ranging from 0 ('clear') to 4 ('severe'); higher scores indicate greater symptom severity.

Time frame:
Week 8
Reported as:
Count of participants · Participants
Number of Participants Achieving Score of 'Clear' in I-IGA at Week 8
ParticipantsRofumilast Cream 0.3%Vehicle Cream
Number of Participants Achieving Score of 'Clear' in I-IGA at Week 8333
Statistical analysis
  • Rofumilast Cream 0.3% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.003 · Odds ratio (or): 29.36 · 95% CI 2.99 to 288.36Common odds ratio stratified by pooled study site and baseline IGA per randomization with multiple imputation of missing data.
SecondaryNumber of Participants Achieving Worst Itch Numerical Rating Score (WI-NRS) Success

The number of participants achieving success in WI-NRS is presented. Success is defined as achievement of a ≥ 4-point reduction in WI-NRS pruritus score in participants with WI-NRS pruritus score ≥ 4 at baseline. The WI-NRS is a 10 point scale ranging from 0 ('no itch') to 10 ('worst itch imaginable'), with higher scores indicating greater symptoms severity. Results are based on observed data only.

Time frame:
Baseline (Day 1) and Weeks 2, 4, and 8
Reported as:
Count of participants · Participants
Number of Participants Achieving Worst Itch Numerical Rating Score (WI-NRS) Success
ParticipantsRofumilast Cream 0.3%Vehicle Cream
Week 2 Observed Data7324
Week 4 Observed Data10118
Week 8 Observed Data12926
Statistical analysis
  • Rofumilast Cream 0.3% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.1197 · Odds ratio (or): 1.76 · 95% CI 0.98 to 3.19Common odds ratio stratified by pooled study site, baseline IGA, and baseline intertriginous involvement per randomization with multiple imputation of missing data.
  • Rofumilast Cream 0.3% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 4.36 · 95% CI 2.31 to 8.26Common odds ratio stratified by pooled study site, baseline IGA, and baseline intertriginous involvement per randomization with multiple imputation of missing data.
  • Rofumilast Cream 0.3% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 7.84 · 95% CI 3.85 to 15.94Common odds ratio stratified by pooled study site, baseline IGA, and baseline intertriginous involvement per randomization with multiple imputation of missing data.
SecondaryChange From Baseline in Psoriasis Symptoms Diary (PSD) Score

The PSD is a 16-item questionnaire asking subjects to rate the severity of psoriasis-related symptoms in the past 24 hours. Each question is scored from 0 ("no symptoms") to 10 ("worst imaginable symptoms"). Scores range from 0 to 160, with higher scores indicating greater symptom severity. The least squares (LS) mean (95% CI) change in PSD total score relative to baseline is presented for each treatment arm, with decreases from baseline indicating symptom improvement.

Time frame:
Weeks 4 and 8
Reported as:
Least squares mean · score on a scale
Change From Baseline in Psoriasis Symptoms Diary (PSD) Score
score on a scaleRofumilast Cream 0.3%Vehicle Cream
Week 4-43.5 (-48.2 to -38.9)-17.7 (-23.5 to -11.9)
Week 8-50.1 (-55.0 to -45.1)-19.2 (-25.3 to -13.0)
Statistical analysis
  • Rofumilast Cream 0.3% vs Vehicle Cream · ANCOVA · p = <0.0001 · Mean difference (final values): -25.83 · 95% CI -31.7 to -20.0Site, baseline IGA, baseline intertriginous involvement, and baseline PSD scores were independent variables, multiple imputation used for missing data
  • Rofumilast Cream 0.3% vs Vehicle Cream · ANCOVA · p = <0.0001 · Mean difference (final values): -30.9 · 95% CI -37.2 to -24.6Site, baseline IGA, baseline intertriginous involvement, and baseline PSD scores were independent variables, multiple imputation used for missing data

Adverse events

Collected over Up to 121 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rofumilast Cream 0.3%0/286 (0%)2/286 (0.7%)0/286 (0%)
Vehicle Cream0/153 (0%)1/153 (0.7%)0/153 (0%)
Most frequent serious events
Most frequent serious events
EventRofumilast Cream 0.3%Vehicle Cream
Plasma cell myelomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2861/153
ConcussionInjury, poisoning and procedural complications1/2860/153
Foot fractureInjury, poisoning and procedural complications1/2860/153
Deformity thoraxMusculoskeletal and connective tissue disorders1/2860/153
PneumothoraxRespiratory, thoracic and mediastinal disorders1/2860/153

Baseline characteristics

Age, Continuous
Age, Continuous(years)Rofumilast Cream 0.3%Vehicle CreamTotal
Mean47.6 ± 14.0948.7 ± 15.7748.0 ± 14.69
Sex: Female, Male
Sex: Female, Male(Participants)Rofumilast Cream 0.3%Vehicle CreamTotal
Female9757154
Male18996285
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Rofumilast Cream 0.3%Vehicle CreamTotal
Hispanic or Latino633497
Not Hispanic or Latino223119342
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Rofumilast Cream 0.3%Vehicle CreamTotal
American Indian or Alaska Native415
Asian211132
Native Hawaiian or Other Pacific Islander202
Black or African American8816
White234124358
More than one race213
Other15823
Whole Body Investigator Global Assessment (IGA) Baseline Score
Whole Body Investigator Global Assessment (IGA) Baseline Score(Participants)Rofumilast Cream 0.3%Vehicle CreamTotal
0 - Clear000
1 - Almost Clear000
2 - Mild512071
3 - Moderate206122328
4 - Severe291140
Intertriginous Area Investigator Global Assessment (I-IGA) Baseline Score
Intertriginous Area Investigator Global Assessment (I-IGA) Baseline Score(Participants)Rofumilast Cream 0.3%Vehicle CreamTotal
0 - Clear000
1 - Almost Clear516
2 - Mild331649
3 - Moderate271643
4 - Severe303
Baseline Psoriasis Symptom Diary (PSD) Total Baseline Score
Baseline Psoriasis Symptom Diary (PSD) Total Baseline Score(score on a scale)Rofumilast Cream 0.3%Vehicle CreamTotal
Mean72.1 ± 42.7573.4 ± 41.2972.6 ± 42.21
Worst Itch Numerical Rating Scale (WI-NRS) Baseline Score
Worst Itch Numerical Rating Scale (WI-NRS) Baseline Score(Participants)Rofumilast Cream 0.3%Vehicle CreamTotal
0161228
111516
2141125
3261036
426733
5321446
6372663
7342054
8492372
9201939
1020626
08

Study locations

40 sites
  • Arcutis Biotherapeutics Clinical Site 127
    Encinitas, California 92024, United States
  • Arcutis Biotherapeutics Clinical Site 112
    Fremont, California 94538, United States
  • Arcutis Biotherapeutics Clinical Site 120
    Irvine, California 92697, United States
  • Arcutis Biotherapeutics Clinical Site 123
    San Diego, California 92123, United States
  • Arcutis Biotherapeutics Clinical Site 136
    San Francisco, California 94132, United States
  • Arcutis Biotherapeutics Clinical Site 118
    Delray Beach, Florida 33484, United States
  • Arcutis Biotherapeutics Clinical Site 131
    Miami, Florida 33174, United States
  • Arcutis Biotherapeutics Clinical Site 137
    Ocala, Florida 34470, United States
  • Arcutis Biotherapeutics Clinical Site 105
    Sanford, Florida 32771, United States
  • Arcutis Biotherapeutics Clinical Site 114
    Plainfield, Illinois 46168, United States
  • Arcutis Biotherapeutics Clinical Site 102
    Rolling Meadows, Illinois 60008, United States
  • Arcutis Biotherapeutics Clinical Site 111
    Baton Rouge, Louisiana 70809, United States
  • Arcutis Biotherapeutics Clinical Site 125
    Rockville, Maryland 20850, United States
  • Arcutis Biotherapeutics Clinical Site 138
    Rockville, Maryland 20850, United States
  • Arcutis Biotherapeutics Clinical Site 101
    Brighton, Massachusetts 02135, United States
  • Arcutis Biotherapeutics Clinical Site 116
    Clinton Township, Michigan 48038, United States
  • Arcutis Biotherapeutics Clinical Site 139
    Reno, Nevada 89509, United States
  • Arcutis Biotherapeutics Clinical Site 129
    East Windsor, New Jersey 08520, United States
  • Arcutis Biotherapeutics Clinical Site 121
    New York, New York 10029, United States
  • Arcutis Biotherapeutics Clinical Site 130
    Rochester, New York 14623, United States
  • Arcutis Biotherapeutics Clinical Site 108
    Stony Brook, New York 11790, United States
  • Arcutis Biotherapeutics Clinical Site 115
    High Point, North Carolina 27262, United States
  • Arcutis Biotherapeutics Clinical Site 124
    Fairborn, Ohio 45324, United States
  • Arcutis Biotherapeutics Clinical Site 134
    Oklahoma City, Oklahoma 73118, United States
  • Arcutis Biotherapeutics Clinical Site 128
    Duncansville, Pennsylvania 16635, United States
  • Arcutis Biotherapeutics Clinical Site 113
    Exton, Pennsylvania 19003, United States
  • Arcutis Biotherapeutics Clinical Site 135
    Pittsburgh, Pennsylvania 15213, United States
  • Arcutis Biotherapeutics Clinical Site 104
    College Station, Texas 77845, United States
  • Arcutis Biotherapeutics Clinical Site 119
    Dallas, Texas 75246, United States
  • Arcutis Biotherapeutics Clinical Site 110
    San Antonio, Texas 78218, United States
  • Arcutis Biotherapeutics Clinical Site 117
    San Antonio, Texas 78229, United States
  • Arcutis Biotherapeutics Clinical Site 132
    Calgary, Alberta T1Y 0B4, Canada
  • Arcutis Biotherapeutics Clinical Site 103
    London, Ontario N6H 5L5, Canada
  • Arcutis Biotherapeutics Clinical Site 122
    Markham, Ontario L3P 1X2, Canada
  • Arcutis Biotherapeutics Clinical Site 133
    Mississauga, Ontario L5H 1G9, Canada
  • Arcutis Biotherapeutics Clinical Site 140
    Ottawa, Ontario K2C 3N2, Canada
  • Arcutis Biotherapeutics Clinical Site 109
    Peterborough, Ontario K9J 5K2, Canada
  • Arcutis Biotherapeutics Clinical Site 106
    Waterloo, Ontario N2J 1C4, Canada
  • Arcutis Biotherapeutics Clinical Site 107
    Montreal, Quebec H3Z 2S6, Canada
  • Arcutis Biotherapeutics Clinical Site 126
    Québec, Quebec G1V4X7, Canada
09

References and documents

Publications

  • Lebwohl MG, Kircik LH, Moore AY, Stein Gold L, Draelos ZD, Gooderham MJ, Papp KA, Bagel J, Bhatia N, Del Rosso JQ, Ferris LK, Green LJ, Hebert AA, Jones T, Kempers SE, Pariser DM, Yamauchi PS, Zirwas M, Albrecht L, Devani AR, Lomaga M, Feng A, Snyder S, Burnett P, Higham RC, Berk DR. Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials. JAMA. 2022 Sep 20;328(11):1073-1084. doi: 10.1001/jama.2022.15632. PubMed 36125472 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Nov 2020, 10 months.

Results were first posted in Nov 2022, 1 year 11 months after primary completion. A results delay was requested in Sep 2021.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 10 months is below that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2019
First posted
Dec 26, 2019
StartActual
Dec 20, 2019
Primary completionActual
Nov 16, 2020
CompletionActual
Nov 16, 2020
Results delay requested
Sep 29, 2021
Results first posted
Nov 3, 2022
Last update
Dec 7, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04211363
Responsible party
Sponsor
First posted
Dec 26, 2019
Start date
Dec 20, 2019
Primary completion
Nov 16, 2020
Completion
Nov 16, 2020
Results posted
Nov 3, 2022
Last update
Dec 7, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roflumilast

Start the discussion